Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

By J. Hrkach, D. V. Von Hoff, M. Ali, E. Andrianova, Jason Auer, Tarikh Campbell, David De Witt, Michael A Figa, Maria Figueiredo, Allen T. Horhota and 20 more. Science Translational Medicine, 2012

1,110 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/83c0803d2afc2620214b0823717133dac5e74466

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Jun Wu
2. O. Farokhzad
3. S. Mitragotri
4. N. Bertrand
5. F. Danhier
6. A. Anselmo
7. Robert Langer
8. N. Kamaly

In Biomedical Engineering

1. Jun Wu
2. O. Farokhzad
3. N. Bertrand
4. S. Mitragotri
5. N. Kamaly
6. Robert Langer
7. F. Danhier
8. A. Anselmo

In Pulmonary and Respiratory Medicine

1. K. El-Say
2. Hossam S. El-Sawy
3. Rakesh K. Jain
4. S. Mitragotri

Citations in the corpus

• Nanoparticles in the clinic (2016, methodology): “While this should not be introduced in the clinic or for direct human testing, efforts to systematically optimize nanoparticles preclinically will likely yield better performance clinical trials.(91) 5.”
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “In vitro feasibility of Apt-decorated NPs to target the prostate-specific membrane antigen (PSMA) cancer marker was reported in 2004 [286].”
• Insight into nanoparticle cellular uptake and intracellular targeting (2014, positive): “In this regard, a notable example is represented by the BIND-014, docetaxel leaded polymer (PLA-PEG and PLGA-PEG) based nanomedicine in Phase II clinical trial, designed for targeted delivery by employing a small molecule ligand (S,S-2-[3-[5-amino-1carboxypentyl]-ureido]-pentanedioic acid, ACUPA) ag”
• Polymeric nanoparticles: Promising platform for drug delivery. (2017, background): “For applications in drug oral delivery science, most NPs are fabricated from biocompatible and biodegradable polymers which agreed by the US Food and Drug Administration (FDA) to be safe for human use (Hrkach et al., 2012).”
• Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology (2013, background): “In preclinical studies, BIND-014 increased the concentration of docetaxel in PSMA-expressing solid tumor xenografts by 5-10-fold.”
• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, methodology): “, targeting moieties, charge modification, stealth), size, shape, and other particle characteristics that can be screened in order to find the best particle properties for patient-specific therapeutics [6].”
• Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, background): “[33] generated a comprehensive series of PEG-polyester nanoparticles, examining 63 Ernsting et al.”